+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 11 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are conducting a national, multicenter, prospective observational study focusing on molecular profiling and first-line treatment approaches for patients with aggressive advanced endometrial cancer stage III-IV in the Russian Federation. The study aims to collect real-world data on the prevalence of specific molecular markers such as POLE mutations, mismatch repair status, p53 abnormalities, HER2, and PD-L1 expression, alongside demographic and clinical characteristics of these patients. The study will include approximately 500 female patients newly diagnosed with aggressive advanced endometrial cancer subtypes who have available biopsy or postoperative archival tumor samples. No additional procedures beyond routine clinical practice will be performed. Molecular testing will be conducted centrally using immunohistochemistry and genetic sequencing techniques on tumor samples. Data collection will occur during two visits the baseline visit to gather demographic, clinical, and treatment information, and a follow-up visit six months later or at disease progression to collect further treatment and progression data. Participants will have their clinical and molecular data entered into electronic records by study physicians. The study will monitor several primary outcomes related to the rates of molecular marker positivity over 24 months and secondary outcomes including chemotherapy use, disease progression, patient demographics, and tumor characteristics over 33 months. The total study duration is expected to be about 27 months or until 500 eligible patients have been enrolled and their data collected, including follow-up.

Age: 18Years +FEMALE
19 locations
O

Actively Recruiting

Researchers are conducting a large observational study involving 5,000 adult patients across about 50 regions in Russia who have uncontrolled severe asthma and are receiving standard treatments except biologic therapies. The study aims to better understand the characteristics, treatment patterns, and clinical outcomes of these patients, as there is currently limited data on this population in Russia. The study will not interfere with routine clinical care and is designed to collect comprehensive real-world information. Participants will have one study visit to gather demographic and clinical data without any additional diagnostic or therapeutic procedures beyond their usual care. This cross-sectional study will take place at 50 outpatient centers experienced in treating uncontrolled severe asthma, enrolling about 100 patients per region. The study will run from June 2024 to June 2027. During the single visit, researchers will collect information such as patients treatment regimens, use of oral corticosteroids, demographic details, clinical characteristics including comorbidities, lung function, and biomarkers like blood eosinophil counts and Immunoglobulin E levels. They will analyze these data to characterize treatment patterns and clinical outcomes in this population. No interventions are given, and patient safety is monitored through standard medical practice.

Age: 18Years +All Genders
40 locations
S

Actively Recruiting

Researchers are evaluating the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of the study drug BCD-261 in patients with moderate to severe active Crohns Disease. This study involves adult men and women aged 18 to 75 years who have had an inadequate response to previous treatments such as glucocorticoids, immunosuppressants, or biologics. The trial is designed to better understand the dose-response relationship of BCD-261 compared to a placebo in this patient group. Participants are randomly assigned to one of five groups receiving different dosing regimens of BCD-261 or placebo. Four groups receive varying doses of BCD-261 low, medium, high during induction weeks 0-12 and maintenance phases, with some groups transitioning between doses. The fifth group receives placebo until the primary endpoint assessment at week 14, after which they switch to the medium dose of BCD-261. During the study, participants will be closely monitored for clinical remission and endoscopic response at week 14, with additional remission assessments at week 24. The study includes comprehensive evaluations such as safety monitoring and pharmacokinetic and pharmacodynamic assessments. Participants will be involved throughout the induction and maintenance periods with scheduled visits and assessments to track treatment effects and safety over time.

Age: 18Years - 75YearsAll GendersPhase 2
20 locations
T

Actively Recruiting

This research aims to understand brain network problems and how they recover during rehabilitation with spinal cord stimulation SCS in people with spinal cord injuries. It focuses on recording resting-state EEG to track brain function changes and explore how brain neuroplasticity plays a role when effective SCS programs are used with implanted electrodes. The study includes participants with either partial or complete spinal cord injuries at various levels. Participants first have resting-state EEG recordings before and after implanting multichannel electrodes into the epidural space below the injury. The spinal cord stimulator is then activated, and optimal stimulation programs are selected to either reduce spasticity or improve voluntary muscle control. Throughout the rehabilitation, EEG recordings are taken before, during, and after stimulation, including a final recording before discharge. The stimulation parameters are adjusted systematically over about two weeks to maximize effectiveness and comfort. During the study, participants follow motor imagery exercises imagining and then performing limb movements while EEG is recorded with the stimulator both off and on. Researchers monitor changes in EEG rhythms and connectivity, focusing on measures like mu rhythm desynchronization. The study also uses clinical scales for neurological function and quality of life at baseline. Postoperative monitoring continues for up to two weeks to ensure safety and track progress. The collected data aims to improve rehabilitation strategies and personalize recovery after spinal cord injury.

All AgesAll GendersPhase Not Applicable
3 locations
C

Actively Recruiting

Researchers are evaluating postoperative pain relief methods in patients undergoing coronary artery bypass grafting CABG. This clinical trial compares the effects of tafalgin tyrosyl-D-arginyl-phenylalanyl-glycine amide with morphine to see if tafalgin reduces pain scores similarly to morphine. The study also monitors the medical problems participants may experience while using tafalgin. This trial is interventional and randomized with a single-blind design. Participants are assigned to one of two groups one group receives a single subcutaneous dose of morphine 10 mg based on a pain score greater than 3 within 24 hours after CABG. The other group receives a single subcutaneous dose of tafalgin 0.4 mg under the same pain score condition and timeframe. The trial focuses on early postoperative pain control in the first 24 hours after surgery. During the study, researchers assess pain using the Visual Analogue Scale VAS 24 hours after CABG. They also evaluate arterial blood gases, including pH, oxygen levels PaO2, and carbon dioxide levels PaCO2, as well as hemodynamic parameters like intra-arterial blood pressure and heart rate. Participants are monitored closely for safety and efficacy during this period. The study is scheduled to start in December 2025 and continue until March 2026.

Age: 18Years - 75YearsAll GendersPhase Not Applicable
1 location
I

Actively Recruiting

Researchers are studying pain management in patients undergoing cardiac surgery, specifically focusing on the use of intrapleural analgesia with ropivacaine. This method involves delivering local anesthetics directly into the pleural cavity through drainage tubes placed after surgery. The study aims to evaluate whether ropivacaine improves the quality of recovery from anesthesia compared to a placebo, especially when traditional pain treatments might pose risks. Participants will receive either 0.2% ropivacaine or a 0.9% sodium chloride placebo infused into the pleural cavity during surgery before closing the chest bone. The infusion starts at 10 ml per hour and continues through a microcatheter placed in the pleural cavity. This randomized, double-blind, placebo-controlled trial monitors patients after surgery to compare these treatments. During the study, participants will be assessed for their recovery quality 24 hours after surgery using the QoR15 questionnaire. Additional measures include oxygenation levels at 6, 12, and 24 hours, morphine use within 24 hours, and pain levels at multiple time points up to 48 hours after surgery. Safety and response to treatment will be closely monitored throughout the recovery period.

Age: 18Years +All GendersPhase 4
2 locations
S

Actively Recruiting

Researchers are evaluating how Lipoproteina Lpa levels vary among patients with Atherosclerotic Cardiovascular Disease ASCVD in Russia and investigating the relationship between elevated Lpa levels and cardiovascular disease risk. The study aims to better understand the distribution of Lpa and its connection to cardiovascular events in this population. The study includes several phases Phase I is a cross-sectional study measuring Lpa levels in ASCVD patients aged 18 and older. Phase II involves a non-interventional, prospective cohort study with these patients and their first-degree relatives, including parents and children with elevated Lpa levels. The study observes patients and relatives over time without altering their treatments. Participants will undergo assessments to measure Lpa levels and cardiovascular events at baseline and during follow-up visits up to 24 months. Researchers will collect clinical data, including disability status, cardiovascular events, hospitalizations, and lipid-lowering therapy usage. The study monitors the percentage of patients with elevated Lpa, occurrence of cardiovascular complications, and treatment outcomes to understand the impact of Lpa levels on ASCVD progression and related health events.

Age: 18Years - 99YearsAll Genders
20 locations
O

Actively Recruiting

Researchers are evaluating the effectiveness of adjuvant ribociclib combined with hormone therapy using aromatase inhibitors with or without GnRH agonists in patients with hormone receptor-positive HR HER2-negative stage II-III breast cancer. This observational study includes two groups a prospective cohort receiving ribociclib plus aromatase inhibitors, and a retrospective cohort treated with aromatase inhibitor monotherapy. The study aims to analyze outcomes based on tumor grade, lymph node involvement, and hormone therapy response in real-world clinical practice in Russia. Participants in the prospective group receive ribociclib along with aromatase inhibitors GnRH agonists, while the retrospective group includes patients treated with aromatase inhibitor monotherapy. Data collection includes both primary prospective data and secondary retrospective data from medical records. The study does not involve experimental treatment assignments but observes existing treatment patterns and outcomes. Participants will be monitored over several years with assessments at months 36, 48, and 60 to evaluate invasive breast cancer-free survival and other related outcomes. Quality of life questionnaires and safety data including adverse events are collected at multiple time points up to 60 months. The study involves continuous data review to assess treatment adherence, disease recurrence, and patient well-being throughout the observation period.

Age: 18Years - 99YearsAll Genders
42 locations
N

Actively Recruiting

Researchers are conducting a national multicenter observational study to develop a Russian national calculator for predicting the risk of postoperative complications and mortality. The study focuses on adult patients undergoing elective and emergency surgeries in various surgical fields including obstetrics, gynecology, urology, orthopedics, and more. The aim is to identify risk factors that lead to unfavorable postoperative outcomes and to create a comprehensive database for better understanding and prediction of surgical risks. The study includes two cohorts Cohort A will assess the incidence of primary outcomes such as 30-day mortality and complications, and Cohort B will identify risk factors and develop a risk calculator validated across different surgical specialties. Data collection involves filling out basic and additional checklists quarterly across centers to capture detailed surgical and postoperative information. The study period spans from 2024 to 2028 with monitoring of outcomes up to one year after surgery. Participants will be followed for various outcomes including 30-day and 90-day mortality and complications, length of stay in intensive care and hospital, multiple organ failure, ICU syndrome, readmission rates, and one-year mortality. Researchers will analyze long-term results and the influence of factors such as anesthesia type, urgency of surgery, age, comorbidities, and oncological conditions. The study is organized by the Russian Federation of Anesthesiologists and Reanimatologists and aims to improve postoperative care through validated risk assessment tools integrated into a national calculator.

Age: 18Years +All Genders
16 locations
S

Actively Recruiting

Researchers are evaluating the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of BCD-261, a study drug, in adults aged 18 to 75 years with moderate to severe active ulcerative colitis who have not responded adequately to previous treatments such as glucocorticoids, immunosuppressants, or biologics. This Phase 2 randomized, double-blind, placebo-controlled study aims to understand the dose-response relationship of BCD-261 in this patient population. Participants will be randomly assigned to one of five groups to receive different doses of BCD-261 or placebo. Four groups receive varied doses of BCD-261low, medium, or highduring an induction period once every 4 weeks until Week 12 followed by a maintenance period once every 8 weeks from Week 20 to Week 100 with adjusted doses. The placebo group receives injections at Weeks 0, 4, 8, and 12, then switches to BCD-261 medium dose injections every 4 weeks until Week 28, followed by a low dose every 8 weeks until Week 100. During the study, participants will be monitored regularly with assessments at specific weeks, including evaluating clinical remission at Week 14 as the primary outcome. Additional measurements at Week 24 and ongoing safety monitoring will be performed. The study involves injections, regular follow-up visits, and evaluations of disease activity, safety, and drug effects over nearly two years to gather comprehensive data on BCD-261s impact in ulcerative colitis.

Age: 18Years - 75YearsAll GendersPhase 2
20 locations

1-10 of 11

1